PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
 
Hum Genet. Mar 2011; 129(3): 273–282.
Published online Dec 4, 2010. doi:  10.1007/s00439-010-0924-2
PMCID: PMC3036835
Investigation of 15 of the top candidate genes for late-onset Alzheimer’s disease
Olivia Belbin,1,2 Minerva M. Carrasquillo,1 Michael Crump,1 Oliver J. Culley,1 Talisha A. Hunter,1 Li Ma,1 Gina Bisceglio,1 Fanggeng Zou,1 Mariet Allen,1,3 Dennis W. Dickson,1 Neill R. Graff-Radford,4 Ronald C. Petersen,5 Kevin Morgan,2 and Steven G. Younkincorresponding author1
1Department of Neuroscience, Mayo Clinic College of Medicine, Jacksonville, FL 32224 USA
2Human Genetics, School of Molecular Medical Sciences, University Hospital, Queen’s Medical Centre, Nottingham, NG7 2UH UK
3MRC Human Genetics Unit, The Institute of Genetics and Molecular Medicine, Western General Hospital, Edinburgh, EH4 2XU UK
4Department of Neurology, Mayo Clinic College of Medicine, Jacksonville, FL 32224 USA
5Department of Neurology and the Mayo Alzheimer Disease Research Center, Mayo Clinic College of Medicine, Rochester, MN 55905 USA
Steven G. Younkin, Phone: +1-904-9537353, Fax: +1-904-9537370, younkin.steven/at/mayo.edu.
corresponding authorCorresponding author.
Received August 24, 2010; Accepted November 19, 2010.
The 12 genome-wide association studies (GWAS) published to-date for late-onset Alzheimer’s disease (LOAD) have identified over 40 candidate LOAD risk modifiers, in addition to apolipoprotein (APOE) ε4. A few of these novel LOAD candidate genes, namely BIN1, CLU, CR1, EXOC3L2 and PICALM, have shown consistent replication, and are thus credible LOAD susceptibility genes. To evaluate other promising LOAD candidate genes, we have added data from our large, case–control series (n = 5,043) to meta-analyses of all published follow-up case–control association studies for six LOAD candidate genes that have shown significant association across multiple studies (TNK1, GAB2, LOC651924, GWA_14q32.13, PGBD1 and GALP) and for an additional nine previously suggested candidate genes. Meta-analyses remained significant at three loci after addition of our data: GAB2 (OR = 0.78, p = 0.007), LOC651924 (OR = 0.91, p = 0.01) and TNK1 (OR = 0.92, p = 0.02). Breslow–Day tests revealed significant heterogeneity between studies for GAB2 (p < 0.0001) and GWA_14q32.13 (p = 0.006). We have also provided suggestive evidence that PGBD1 (p = 0.04) and EBF3 (p = 0.03) are associated with age-at-onset of LOAD. Finally, we tested for interactions between these 15 genes, APOE ε4 and the five novel LOAD genes BIN1, CLU, CR1, EXOC3L2 and PICALM but none were significant after correction for multiple testing. Overall, this large, independent follow-up study for 15 of the top LOAD candidate genes provides support for GAB2 and LOC651924 (6q24.1) as risk modifiers of LOAD and novel associations between PGBD1 and EBF3 with age-at-onset.
Electronic supplementary material
The online version of this article (doi:10.1007/s00439-010-0924-2) contains supplementary material, which is available to authorized users.
Genome-wide association studies represent a powerful approach for identifying putative candidate genes for common complex disorders, such as LOAD. To-date, 12 GWAS of LOAD have been published (Coon et al. 2007; Grupe et al. 2007; Abraham et al. 2008; Bertram et al. 2008; Li et al. 2008; Beecham et al. 2009; Carrasquillo et al. 2009; Harold et al. 2009; Lambert et al. 2009; Poduslo et al. 2009; Potkin et al. 2009; Seshadri et al. 2010) revealing more than 40 candidate variants that modify LOAD risk independent of APOE (and genes likely to be in linkage disequilibrium with APOE such as TOMM40, APOC1 and APOC2). Notably, CLU is the only signal besides these four APOE-related signals to be identified in more than one GWAS at a genome-wide significant level (Harold et al. 2009; Lambert et al. 2009).
Follow-up case–control association studies of the 40+ candidate loci identified by GWAS are vital in order to filter out any false-positive signals and to provide further evidence for genetic association of the truly functional genes. We have successfully replicated (Carrasquillo et al. 2010) the association of variants in CLU, CR1 and PICALM identified by two large GWAS (Harold et al. 2009; Lambert et al. 2009) thus providing compelling support for these genes as true candidate LOAD genes. Two other recently GWAS-identified signals in EXOC3L2 and BIN1 (Seshadri et al. 2010) are currently being investigated for replication in our large case–control series.
In addition to these candidates, AlzGene (http://www.Alzgene.org) meta-analyses of all published LOAD association studies have revealed significant association for six other GWAS-identified variants (TNK1, GAB2, LOC651924, GWA_14q32.13, PGBD1 and GALP) that are now ranked among the Top 50 LOAD candidate genes on the AlzGene website (Bertram et al. 2006). Although, many variants have yet to be tested in follow-up studies, these six loci currently represent compelling GWAS signals worthy of follow-up investigation (Bertram and Tanzi 2009).
Here we evaluate in our large case–control series (n = 5,043) the most significant variants in TNK1, GAB2, LOC651924, GWA_14q32.13, PGBD1 and GALP for genetic association with LOAD, as well as nine previously suggested candidate LOAD genes (Grupe et al. 2007). We have performed meta-analyses of all available published case–control series including our data and investigated the effect of heterogeneity on the ORs between series. We also tested for association of these 15 variants with age-at-onset of LOAD and for epistatic interaction with APOE ε4, BIN1, CLU, CR1, EXOC3L2 and PICALM.
Case–control subjects
The case–control series consisted of 5,043 Caucasian subjects from the United States (2,455 AD, 2,588 control) ascertained at the Mayo Clinic (1,753 AD, 2,379 controls) or through the National Cell Repository for Alzheimer’s Disease (NCRAD: 702 AD, 209 control). All subjects ascertained at the Mayo Clinic in Jacksonville, Florida (JS: 602 AD, 604 control) and at the Mayo Clinic in Rochester, Minnesota, (RS: 553 AD, 1,399 control) were diagnosed by a Mayo Clinic neurologist. The neurologist confirmed a clinical dementia rating score of 0 for all JS and RS subjects enrolled as controls; cases had diagnoses of possible or probable AD made according to NINCDS-ADRDA criteria (McKhann et al. 1984). In the autopsy-confirmed series (AUT: 598 AD, 376 control), all brains were evaluated by Dr. Dennis Dickson and came from the brain bank maintained at the Mayo Clinic in Jacksonville, FL. In the AUT series the diagnosis of definite AD was also made according to NINCDS-ADRDA criteria. All AD brains analyzed in the study had a Braak score of 4.0 or greater. Brains employed as controls had a Braak score of 2.5 or lower but often had brain pathology unrelated to AD and pathological diagnoses that included vascular dementia, fronto-temporal dementia, dementia with Lewy bodies, multi-system atrophy, amyotrophic lateral sclerosis, and progressive supranuclear palsy. One AD case from each of the 702 late-onset NCRAD families was analyzed. NCRAD AD cases were selected based on strength of diagnosis (autopsy-confirmed, 32% > probable, 45% > possible, 8% > family report, 15%); the case with the earliest age at diagnosis was taken when several cases had equally strong diagnoses. The 209 NCRAD controls that we employed were unrelated Caucasian subjects from the United States with a clinical dementia rating of 0, specifically collected for inclusion in case–control series. All individuals with an age-at-diagnosis <60 or with mutations in PSEN1, PSEN2 or APP were removed from analyses. The mean age-at-diagnosis, percentage that are female and percentage that possess at least one copy of the APOE ε4 allele for each series are shown in Online Resource 1.
DNA isolation
For the JS and RS samples, DNA was isolated from whole blood using an AutoGen instrument (AutoGen, Inc, Holliston, MA). The DNA from AUT samples was extracted from cerebellum using Wizard® Genomic DNA Purification Kits (Promega Corp., Madison, WI). DNA from the RS and AUT series was scarce, so samples from these two series were subjected to whole genome amplification using the Illustra GenomiPhi V2 DNA Amplification Kit (GE Healthcare Bio-Sciences Corp., Piscataway, NJ).
Genotyping of variants
All genotyping was performed on 384-well plate formats containing on average eight (min = 4, max = 14) negative controls per plate. We ensured that each plate had a mixture of cases and controls. Positive controls were not included on these plates. GAB2 and PGBD1 variants were genotyped at the Mayo Clinic in Jacksonville using TaqMan® SNP Genotyping Assays in an ABI PRISM® 7900HT Sequence Detection System with 384-Well Block Module from Applied Biosystems, California, USA. The genotype data was analyzed using the SDS software version 2.2.2 (Applied Biosystems, California, USA). Genotype information for BIN1 (rs744373), EXOC3L2 (rs597668), MYH13 (rs2074877), PCK1 (rs8192708) and TRAK2 (rs1302344), were available from our GWAS (Carrasquillo et al. 2009). All other variants were genotyped using SEQUENOM’s MassArray iPLEX technology (SEQUENOM Inc, San Diego, CA) following the manufacturer’s instructions. Genotype calls were made using the default post-processing calling parameters in SEQUENOM’s Typer 4.0 software, followed by visual inspection to remove genotype calls that were obviously erroneous based on the presence or absence of allele peaks in an individual sample’s spectrogram, to check that the boundaries of the genotype clusters were non-overlapping and finally to ensure that samples between clusters were not called. Genotyping probe sequences are shown in Online Resource 2. All variants passed the p value cut-off (p > 0.001) for deviation from Hardy–Weinberg equilibrium as suggested by Wigginton et al. when investigating >1,000 samples (Wigginton et al. 2005). Genotyping of variants in CLU, PICALM and CR1 have been reported previously (Carrasquillo et al. 2010).
Statistical analyses
All statistics were performed using StatsDirect v2.5.8 software. Variants were analyzed for association with LOAD by logistic regression (additive/allelic dosage, dominant and recessive models). When included in the analysis, covariates were sex, age at diagnosis/entry, and APOE ε4+/−. Meta-analyses were performed for each individual series including all available published case–control series from Caucasian populations for these variants. Genotype counts for previously published studies were obtained either directly from the publication or from the AlzGene website. Summary ORs and 95% CI were calculated using the DerSimonian and Laird (1986) random-effects model. Breslow–Day tests were used to test for heterogeneity between series. Since age-at-onset of LOAD did not follow a Gaussian distribution, association of the minor allele at each variant with age-at-onset was performed using a Mann–Whitney U test. Tests for epistatic interaction were performed using the Synergy Factor Excel spreadsheet made available by Cortina-Borja et al. (2009). Odds ratios were calculated based on a dominant model for the minor allele, i.e. major allele homozygotes versus heterozygotes and minor allele homozygotes and, in the case of APOE ε4, no-ε4 versus at least one copy of ε4.
We have genotyped 15 candidate LOAD variants initially identified by GWA studies. Genotype and allele counts for these variants in our complete series are shown in Online Resource 3. We first focused on six variants highlighted by Bertram and Tanzi (2009) as the most compelling GWAS signals worthy of follow-up investigation. The initial GWAS findings for these six variants are shown in Table 1a. In order to directly compare our results with these previous studies, we tested for association with LOAD in our case–control series by logistic regression using an additive/allelic dosage model (Table 1b). Although all variants showed significant association with LOAD (all p < 0.0003) in the initial studies, no variants were significantly associated with LOAD risk in our study (all p > 0.07). Furthermore, only two variants had ORs in the same direction [GAB2; Reiman OR = 0.55 (Reiman et al. 2007), Mayo OR = 0.94 and LOC651924; Grupe OR = 0.86 (Grupe et al. 2007), Mayo OR = 0.94]. It must be noted that the Mayo series were larger in number than the initial studies and therefore, in principle, had greater power to detect these associations.
Table 1
Table 1
Replication results for genetic association of six candidate LOAD loci identified by GWAS
In order to determine whether the data from our series would confound the significant meta-analysis reported by AlzGene, we performed our own meta-analyses including our data using the DerSimonian and Laird random-effects model (Table 2). Given that none of the six variants highlighted in the Bertram and Tanzi (2009) showed significant association with risk of LOAD in our case–control series, it is not surprising that the overall ORs for all six variants were closer to 1 when our data (Table 2b) were included (Table 2c) compared to the meta-analyses of all previous studies (Table 2a). However, while significance was diminished following inclusion of our data, the meta-analyses for TNK1 (p = 0.02), GAB2 (p = 0.007) and LOC651924 (p = 0.01) remained significant at the p < 0.05 level. The remaining three loci, though not significant had overall ORs in the same direction as the AlzGene meta-analysis when our data were included.
Table 2
Table 2
Meta-analysis of the six loci for association with LOAD in (a) previously published studies (Grupe et al. 2007; Reiman et al. 2007; Li et al. 2008; Feulner et al. 2009; Figgins et al. 2009; Sleegers et al. 2009) (b) our data and (c) overall; including (more ...)
In order to investigate heterogeneity between studies for these variants, Breslow–Day tests were performed (shown in Table 2; Fig. 1). Forest plots of the OR and 95% CI for each series are shown in Fig. 1. Two variants (GAB2, p < 0.0001; GALP, p = 0.03) showed significant heterogeneity in the previously published data (Table 2a), while in our data (Table 2b) only GAB2 showed significant heterogeneity (p = 0.0002). Overall (Table 2c; Fig. 1), GAB2 showed the most significant heterogeneity (p < 0.0001) followed by GWA_14q32.13 (p = 0.006) and GALP (p = 0.05).
Fig. 1
Fig. 1
Forest plots for meta-analysis for each variant. ORs (boxes) and 95% CI (whiskers) are plotted for each series and shown on the right of each plot. Combined OR is the overall OR calculated by the meta-analysis using a random-effects model. p values from (more ...)
Since some genetic variants may exert dominant or recessive effects we also performed logistic regression using these models and corrected for sex, age at diagnosis/entry, and APOE ε4+/− as covariates (Online Resource 4). Although LOC651924 (OR = 0.85, p = 0.03) and GWA_14q32.13 (OR = 1.18, p = 0.01) gave significant ORs under a dominant model, neither would survive Bonferroni correction for the 60 tests performed.
We next tested for association of the variants with age-at-onset in the 2,455 LOAD patients from our case–control series (Table 3). The only variant to show association at the p < 0.05 level was PGBD1 (p = 0.04) where the minor allele was associated with an age-at-onset 1 year earlier than the major allele, although this weak association would not survive Bonferroni correction (p < 0.003).
Table 3
Table 3
Association of six loci with age-at-onset in LOAD patients
In addition to these six loci, we had genotype information available for nine variants (EBF3, LMNA, BCR, UBD, THEM5, CTSS, TRAK2, MYH13 and PCK1) identified by Grupe et al. (2007). The genotype counts, case–control association, meta-analyses, alternative models, association with age-at-onset and epistatic interactions can be found in Online Resources 3–8. In summary, although all nine variants were associated with LOAD in the initial study (all p < 0.001), logistic regression of our data using an additive/allelic dosage model and no covariates revealed one variant (rs13022344 in TRAK2) significantly associated with LOAD in our series (OR = 0.86, p = 0.02) but in the opposite direction to that reported in the initial study (OR = 1.07, p = 0.001). Notably, EBF3 (p = 0.04), THEM5 (p = 0.03), CTSS (p = 0.03) and TRAK2 (p = 0.02) were associated with LOAD risk under a recessive model whilst correcting for covariates, although these associations would not survive Bonferroni correction for the 60 tests performed (p < 0.0008). None of these nine variants were significant at the p < 0.05 level following meta-analyses either before or after addition of our data (Online Resources 6). Overall, Breslow–Day tests revealed genetic heterogeneity for six (LMNAp = 0.0004, BCRp = 0.04, THEM5p = 0.01, PCK1p = 0.003, CTSSp = 0.02 and TRAK2p = 0.0002) of the nine variants. None of these nine variants were associated with age-at-onset (Online Resources 7) after Bonferroni correction, however, EBF3 showed nominally significant association with a later age-at-onset of 0.8 years (79.0 years) compared to the major allele (78.2 years; p = 0.03).
In order to determine whether these 15 variants interact with other strong LOAD candidates to modify risk for LOAD, we tested for epistatic interaction between the variants studied here and the strongest known LOAD risk factor, APOE ε4, as well as the top GWAS-identified variants for which we had genotype information available; BIN1 (rs744373), CLU (rs11136000), CR1 (rs3818361), EXOC3L2 (rs597668) and PICALM (rs3851179). The results for all 105 tests performed are shown in Online Resource 8. There were seven interactions that were significant at the p ≤ 0.05 level, which are shown in Table 4, however, none would survive Bonferroni correction for the 105 tests performed. Further investigation of these possible epistatic interactions in multiple, independent studies is required in order to determine whether there is true synergy between the variants.
Table 4
Table 4
Epistatic interactions between LOAD candidate genes significant at the p ≤ 0.05 level (total number of tests = 105)
This study used the largest sample size to-date to investigate 15 of the top AlzGene hits (AlzGene, accessed October 2010) which were originally identified in a LOAD GWAS. Meta-analyses remained significant at three loci after addition of our data: GAB2 (rs10793294, OR = 0.78, p = 0.007), LOC651924 (rs6907175, OR = 0.91, p = 0.01) and TNK1 (rs1554948, OR = 0.92, p = 0.02). Although our data alone provided no support for an association of TNK1 with LOAD (OR = 1.00, p = 0.99), the AlzGene meta-analyses odds ratios for both GAB2 (0.69) and LOC651924, (0.89) were well replicated in our series (OR = 0.89 and 0.94, respectively) albeit that neither variant was significant (p = 0.40 and 0.37, respectively). We also investigated nine additional variants (in EBF3, LMNA, BCR, THEM5, PCK1, MYH13, CTSS, UBD and TRAK2) identified by Grupe et al. but found no significant associations following meta-analyses.
Our meta-analyses which include nine independent studies comprising 9,072 individuals provide good evidence that GAB2 (rs10793294 OR = 0.78, p = 0.007) is a genuine candidate LOAD locus. These data are further supported by a recent family-based study (Schjeide et al. 2009a), which revealed significant association of another GAB2 variant (rs7101429) in 399 families (p = 0.002), thus strengthening the evidence for GAB2. In consideration of this association of GAB2 with LOAD in families, we performed our logistic regression (additive model) analyses again on the total dataset with the 112 NCRAD LOAD patients with a family history of AD removed. We found that removing these samples gave a comparable association to our initial analyses (all samples: n = 4,969, OR = 0.94, p = 0.20; no family history: n = 4,857, OR = 0.95, p = 0.36; data not shown). We also found a comparable association of GAB2 with age-at-onset after removal of these samples (all samples: n = 2,416, U = 692,338.5, p = 0.68; no family history: n = 2,304, U = 628,587, p = 0.76; data not shown). Notably, in another family-based study by the same group, eight variants included in this manuscript (GALP, GWA_14q32.13, LMNA, LOC651924, MYH13, PCK1, PGBD1, TNK1) were tested but failed to show association with LOAD in 457 families (Schjeide et al. 2009b); this is compatible with our meta-analyses of variants in GWA_14q32.13 (rs11622883), PGBD1 (rs3800324) and GALP (rs3745833) which revealed no association with LOAD.
Our meta-analyses also provided evidence that LOC651924 is a true candidate locus (OR = 0.91, p = 0.01). Although only one out of the nine series studied revealed significant association (p < 0.05), the effect of the variants were in the same direction (with comparable ORs) in seven of the series. As a result, the meta-analysis revealed significant association thus supporting the evidence for LOC651924 as a LOAD candidate.
The 15 variants we analyzed showed remarkable across-study heterogeneity. The Breslow–Day p values for the initial, Mayo follow-up and overall meta-analyses of the 15 variants we analyzed are summarized in Table 2 and Online Resource 6. Overall, meta-analysis of the variants in four genes (GAB2, TRAK2, LMNA and PCK1) gave Breslow–Day p values ranging from <0.0001 to 0.002 that are significant even after Bonferroni correction for 15 variants analyzed (p < 0.003). The variants in seven genes had nominally significant or highly suggestive Breslow–Day p values that ranged from 0.01 to 0.06, and the variants in the three remaining genes had Breslow–Day p values of 0.12 to 0.25. Thus, our analysis of 15 promising LOAD variants suggests that LOAD variants may often show noteworthy series to series heterogeneity. If the heterogeneity we observed is real and if it occurs as frequently as our data suggest, then many genetic variants may influence LOAD susceptibility in a way that depends on genetic and/or environmental factors that vary from series to series.
It is now clear that, apart from the well-known APOE alleles, common genetic variants have only weak association with LOAD. Whether many of these variants have odds ratios that truly vary because they depend on environmental and/or genetic factors that differ from series to series is currently unclear. What is clear is that variants of this type are likely to be missed if genetic association studies focus exclusively on replicable associations that become highly significant when many series are combined. To find important susceptibility alleles with effects that vary from series, it may be necessary to consider and to understand variants that show significant association in some series and highly significant heterogeneity on meta-analysis even though meta-analysis provides no evidence for association.
It is important to recognize that spurious heterogeneity can occur owing to publication bias wherein only those series that, by chance, have false-positive results are published. When these series are combined with follow-up series with ORs that vary randomly around 1.0, Breslow–Day testing can show significant, but misleading evidence of heterogeneity. One way to mitigate this problem is to determine if, when initial series are eliminated, the follow-up studies show heterogeneity. In the current study, the variants in GAB2 and in LMNA had Breslow–Day p values of 0.0002 and 0.002 in the Mayo follow-up series alone that retain significance even after Bonferroni correction for 15 variants tested. It is worth noting that both the GAB2 and LMNA variants also showed significant heterogeneity in the initial studies with p values of 0.0009 and 0.01, respectively and in the overall meta-analysis with p values of <0.0001 and 0.0004, respectively. Since it appears that two of the 15 variants we studied showed true series to series heterogeneity, it seems appropriate to consider that the heterogeneity observed for many of the other variants may also be real.
One interesting cause of heterogeneity occurs when the “heterogeneous” variant is merely a tag for the truly functional variant (or multiple rare variants each with strong functional effects) and the degree of linkage disequilibrium between these variants differs between series leading to weaker and/or opposing effects. When this is the case, variants (e.g., those in GAB2 and GWA_14q32.13) that show significant heterogeneity between multiple, large, case–control series could be used to identify candidate regions for targeted sequencing and haplotype analysis that resolves the heterogeneity thereby identifying functional variants that show replicable, significant association.
We also investigated whether the 15 variants were associated with age-at-onset. Although we have suggestive evidence that PGBD1 and EBF3 may be associated with age-at-onset and that LMNA may interact with APOE ε4, due to the multiple tests performed and the relatively weak p values obtained (all p > 0.02), we suggest that further investigation into these findings is required in order to determine whether these were merely due to chance or if they represent true associations.
Finally, we tested for pairwise interactions between the 15 variants evaluated in this study as well as with APOE ε4, BIN1 (rs744373), CLU (rs11136000), CR1 (rs3818361), EXOC3L2 (rs597668) and PICALM (rs3851179). Seven pairs showed nominally significant synergy factors (p values ranging from 0.007 to 0.05), but none remained significant after correction for the 105 tests performed (p < 0.0005). It is possible that many epistatic interactions exist between LOAD genes, of which relatively few combinations have been tested here. We therefore propose that future studies of candidate LOAD genes apply tests for epistasis with other candidate genes in order to identify otherwise hidden interactions that could contribute greater risk than any gene individually.
Overall, this study represents a thorough, independent follow-up study of 15 of the top LOAD candidate genes, in a large case–control series and provides further evidence for the association of GAB2 and LOC651924 (6q24.1) with LOAD. In addition, we have provided suggestive evidence that, in our series, two genes (PGBD1 and EBF3) are potentially associated with age-at-onset of LOAD.
The experiments described in this manuscript comply with the current laws of the United States of American where they were performed. Approval was obtained from the ethics committee or institutional review board of each institution responsible for the ascertainment and collection of samples (Mayo Clinic College of Medicine, Jacksonville, FL and Mayo Clinic College of Medicine, Rochester, MN, USA). Written informed consent was obtained for all individuals that participated in this study.
 
Electronic supplementary material
Below is the link to the electronic supplementary material.
Acknowledgments
Samples from the National Cell Repository for Alzheimer’s Disease (NCRAD) were used in this study. We thank contributors, including the Alzheimer’s Disease Centers who collected samples used in this study, as well as patients and their families, whose help and participation made this work possible. This work was supported by grants from the US National Institutes of Health, NIA R01 AG18023 (N.R.G.-R., Steven G. Younkin); Mayo Alzheimer’s Disease Research Center, P50 AG16574 (R.C.P., D.W.D., N.R.G.-R., Steven G. Younkin); Mayo Alzheimer’s Disease Patient Registry, U01 AG06576 (R.C.P.); and US National Institute on Aging, AG25711, AG17216, AG03949 (D.W.D.). Samples from the National Cell Repository for Alzheimer’s Disease (NCRAD), which receives government support under a cooperative agreement grant (U24AG21886) awarded by the National Institute on Aging (NIA), were used in this study. This project was also generously supported by the Robert and Clarice Smith Postdoctoral Fellowship (M.M.C.); Robert and Clarice Smith and Abigail Van Buren Alzheimer’s Disease Research Program (R.C.P., D.W.D., N.R.G.-R.; Steven G. Younkin) and by the Palumbo Professorship in Alzheimer’s Disease Research (Steven G. Younkin). K.M. is funded by the Alzheimer’s Research Trust and the Big Lottery Fund
Conflict of interest The authors declare that they have no conflict of interest.
Open Access This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.
  • Abraham R, Moskvina V, Sims R, Hollingworth P, Morgan A, Georgieva L, Dowzell K, Cichon S, Hillmer AM, O’Donovan MC, Williams J, Owen MJ, Kirov G. A genome-wide association study for late-onset Alzheimer’s disease using DNA pooling. BMC Med Genomics. 2008;1:44. doi: 10.1186/1755-8794-1-44. [PMC free article] [PubMed] [Cross Ref]
  • Beecham GW, Martin ER, Li YJ, Slifer MA, Gilbert JR, Haines JL, Pericak-Vance MA. Genome-wide association study implicates a chromosome 12 risk locus for late-onset Alzheimer disease. Am J Hum Genet. 2009;84(1):35–43. doi: 10.1016/j.ajhg.2008.12.008. [PubMed] [Cross Ref]
  • Bertram L, Tanzi RE. Genome-wide association studies in Alzheimer’s disease. Hum Mol Genet. 2009;18(R2):R137–R145. doi: 10.1093/hmg/ddp406. [PMC free article] [PubMed] [Cross Ref]
  • Bertram L, McQueen M, Mullin K, Blacker D and Tanzi R (2006) The AlzGene database. Available at http://www.alzgene.org. Accessed March 2010.
  • Bertram L, Lange C, Mullin K, Parkinson M, Hsiao M, Hogan MF, Schjeide BM, Hooli B, Divito J, Ionita I, Jiang H, Laird N, Moscarillo T, Ohlsen KL, Elliott K, Wang X, Hu-Lince D, Ryder M, Murphy A, Wagner SL, Blacker D, Becker KD, Tanzi RE. Genome-wide association analysis reveals putative Alzheimer’s disease susceptibility loci in addition to APOE. Am J Hum Genet. 2008;83(5):623–632. doi: 10.1016/j.ajhg.2008.10.008. [PubMed] [Cross Ref]
  • Carrasquillo MM, Zou F, Pankratz VS, Wilcox SL, Ma L, Walker LP, Younkin SG, Younkin CS, Younkin LH, Bisceglio GD, Ertekin-Taner N, Crook JE, Dickson DW, Petersen RC, Graff-Radford NR, Younkin SG. Genetic variation in PCDH11X is associated with susceptibility to late-onset Alzheimer’s disease. Nat Genet. 2009;41(2):192–198. doi: 10.1038/ng.305. [PMC free article] [PubMed] [Cross Ref]
  • Carrasquillo MM, Belbin O, Hunter TA, Ma L, Bisceglio GD, Zou F, Crook JE, Pankratz VS, Dickson DW, Graff-Radford NR, Petersen RC, Morgan K, Younkin SG. Replication of CLU, CR1 and PICALM associations with Alzheimer’s disease. Arch Neurol. 2010;67(8):961–964. doi: 10.1001/archneurol.2010.147. [PMC free article] [PubMed] [Cross Ref]
  • Coon KD, Myers AJ, Craig DW, Webster JA, Pearson JV, Lince DH, Zismann VL, Beach TG, Leung D, Bryden L, Halperin RF, Marlowe L, Kaleem M, Walker DG, Ravid R, Heward CB, Rogers J, Papassotiropoulos A, Reiman EM, Hardy J, Stephan DA. A high-density whole-genome association study reveals that APOE is the major susceptibility gene for sporadic late-onset Alzheimer’s disease. J Clin Psychiatry. 2007;68(4):613–618. doi: 10.4088/JCP.v68n0419. [PubMed] [Cross Ref]
  • Cortina-Borja M, Smith AD, Combarros O, Lehmann DJ. The synergy factor: a statistic to measure interactions in complex diseases. BMC Res Notes. 2009;2:105. doi: 10.1186/1756-0500-2-105. [PMC free article] [PubMed] [Cross Ref]
  • DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7:177–188. [PubMed]
  • Feulner TM, Laws SM, Friedrich P, Wagenpfeil S, Wurst SH, Riehle C, Kuhn KA, Krawczak M, Schreiber S, Nikolaus S, Forstl H, Kurz A, Riemenschneider M. Examination of the current top candidate genes for AD in a genome-wide association study. Mol Psychiatry. 2009;15(7):756–766. doi: 10.1038/mp.2008.141. [PubMed] [Cross Ref]
  • Figgins JA, Minster RL, Demirci FY, Dekosky ST, Kamboh MI. Association studies of 22 candidate SNPs with late-onset Alzheimer’s disease. Am J Med Genet B Neuropsychiatr Genet. 2009;150B(4):520–526. doi: 10.1002/ajmg.b.30851. [PMC free article] [PubMed] [Cross Ref]
  • Grupe A, Abraham R, Li Y, Rowland C, Hollingworth P, Morgan A, Jehu L, Segurado R, Stone D, Schadt E, Karnoub M, Nowotny P, Tacey K, Catanese J, Sninsky J, Brayne C, Rubinsztein D, Gill M, Lawlor B, Lovestone S, Holmans P, O’Donovan M, Morris JC, Thal L, Goate A, Owen MJ, Williams J. Evidence for novel susceptibility genes for late-onset Alzheimer’s disease from a genome-wide association study of putative functional variants. Hum Mol Genet. 2007;16(8):865–873. doi: 10.1093/hmg/ddm031. [PubMed] [Cross Ref]
  • Harold D, Abraham R, Hollingworth P, Sims R, Gerrish A, Hamshere ML, Pahwa JS, Moskvina V, Dowzell K, Williams A, Jones N, Thomas C, Stretton A, Morgan AR, Lovestone S, Powell J, Proitsi P, Lupton MK, Brayne C, Rubinsztein DC, Gill M, Lawlor B, Lynch A, Morgan K, Brown KS, Passmore PA, Craig D, McGuinness B, Todd S, Holmes C, Mann D, Smith AD, Love S, Kehoe PG, Hardy J, Mead S, Fox N, Rossor M, Collinge J, Maier W, Jessen F, Schurmann B, Bussche H, Heuser I, Kornhuber J, Wiltfang J, Dichgans M, Frolich L, Hampel H, Hull M, Rujescu D, Goate AM, Kauwe JS, Cruchaga C, Nowotny P, Morris JC, Mayo K, Sleegers K, Bettens K, Engelborghs S, Deyn PP, Broeckhoven C, Livingston G, Bass NJ, Gurling H, McQuillin A, Gwilliam R, Deloukas P, Al-Chalabi A, Shaw CE, Tsolaki M, Singleton AB, Guerreiro R, Muhleisen TW, Nothen MM, Moebus S, Jockel KH, Klopp N, Wichmann HE, Carrasquillo MM, Pankratz VS, Younkin SG, Holmans PA, O’Donovan M, Owen MJ, Williams J. Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer’s disease. Nat Genet. 2009;41(10):1088–1093. doi: 10.1038/ng.440. [PMC free article] [PubMed] [Cross Ref]
  • Lambert JC, Heath S, Even G, Campion D, Sleegers K, Hiltunen M, Combarros O, Zelenika D, Bullido MJ, Tavernier B, Letenneur L, Bettens K, Berr C, Pasquier F, Fievet N, Barberger-Gateau P, Engelborghs S, Deyn P, Mateo I, Franck A, Helisalmi S, Porcellini E, Hanon O, Pancorbo MM, Lendon C, Dufouil C, Jaillard C, Leveillard T, Alvarez V, Bosco P, Mancuso M, Panza F, Nacmias B, Bossu P, Piccardi P, Annoni G, Seripa D, Galimberti D, Hannequin D, Licastro F, Soininen H, Ritchie K, Blanche H, Dartigues JF, Tzourio C, Gut I, Broeckhoven C, Alperovitch A, Lathrop M, Amouyel P. Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer’s disease. Nat Genet. 2009;41(10):1094–1099. doi: 10.1038/ng.439. [PubMed] [Cross Ref]
  • Li H, Wetten S, Li L, St Jean PL, Upmanyu R, Surh L, Hosford D, Barnes MR, Briley JD, Borrie M, Coletta N, Delisle R, Dhalla D, Ehm MG, Feldman HH, Fornazzari L, Gauthier S, Goodgame N, Guzman D, Hammond S, Hollingworth P, Hsiung GY, Johnson J, Kelly DD, Keren R, Kertesz A, King KS, Lovestone S, Loy-English I, Matthews PM, Owen MJ, Plumpton M, Pryse-Phillips W, Prinjha RK, Richardson JC, Saunders A, Slater AJ, St George-Hyslop PH, Stinnett SW, Swartz JE, Taylor RL, Wherrett J, Williams J, Yarnall DP, Gibson RA, Irizarry MC, Middleton LT, Roses AD. Candidate single-nucleotide polymorphisms from a genomewide association study of Alzheimer disease. Arch Neurol. 2008;65(1):45–53. doi: 10.1001/archneurol.2007.3. [PubMed] [Cross Ref]
  • McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology. 1984;34(7):939–944. [PubMed]
  • Poduslo SE, Huang R, Huang J, Smith S. Genome screen of late-onset Alzheimer’s extended pedigrees identifies TRPC4AP by haplotype analysis. Am J Med Genet B Neuropsychiatr Genet. 2009;150B(1):50–55. doi: 10.1002/ajmg.b.30767. [PubMed] [Cross Ref]
  • Potkin SG, Guffanti G, Lakatos A, Turner JA, Kruggel F, Fallon JH, Saykin AJ, Orro A, Lupoli S, Salvi E, Weiner M, Macciardi F. Hippocampal atrophy as a quantitative trait in a genome-wide association study identifying novel susceptibility genes for Alzheimer’s disease. PLoS One. 2009;4(8):e6501. doi: 10.1371/journal.pone.0006501. [PMC free article] [PubMed] [Cross Ref]
  • Reiman EM, Webster JA, Myers AJ, Hardy J, Dunckley T, Zismann VL, Joshipura KD, Pearson JV, Hu-Lince D, Huentelman MJ, Craig DW, Coon KD, Liang WS, Herbert RH, Beach T, Rohrer KC, Zhao AS, Leung D, Bryden L, Marlowe L, Kaleem M, Mastroeni D, Grover A, Heward CB, Ravid R, Rogers J, Hutton ML, Melquist S, Petersen RC, Alexander GE, Caselli RJ, Kukull W, Papassotiropoulos A, Stephan DA. GAB2 alleles modify Alzheimer’s risk in APOE epsilon4 carriers. Neuron. 2007;54(5):713–720. doi: 10.1016/j.neuron.2007.05.022. [PMC free article] [PubMed] [Cross Ref]
  • Schjeide BM, Hooli B, Parkinson M, Hogan MF, DiVito J, Mullin K, Blacker D, Tanzi RE, Bertram L. GAB2 as an Alzheimer disease susceptibility gene: follow-up of genomewide association results. Arch Neurol. 2009;66(2):250–254. doi: 10.1001/archneurol.2008.552. [PMC free article] [PubMed] [Cross Ref]
  • Schjeide BM, McQueen MB, Mullin K, DiVito J, Hogan MF, Parkinson M, Hooli B, Lange C, Blacker D, Tanzi RE, Bertram L. Assessment of Alzheimer’s disease case–control associations using family-based methods. Neurogenetics. 2009;10(1):19–25. doi: 10.1007/s10048-008-0151-3. [PMC free article] [PubMed] [Cross Ref]
  • Seshadri S, Fitzpatrick AL, Ikram MA, DeStefano AL, Gudnason V, Boada M, Bis JC, Smith AV, Carrasquillo MM, Lambert JC, Harold D, Schrijvers EM, Ramirez-Lorca R, Debette S, Longstreth WT, Jr, Janssens AC, Pankratz VS, Dartigues JF, Hollingworth P, Aspelund T, Hernandez I, Beiser A, Kuller LH, Koudstaal PJ, Dickson DW, Tzourio C, Abraham R, Antunez C, Du Y, Rotter JI, Aulchenko YS, Harris TB, Petersen RC, Berr C, Owen MJ, Lopez-Arrieta J, Varadarajan BN, Becker JT, Rivadeneira F, Nalls MA, Graff-Radford NR, Campion D, Auerbach S, Rice K, Hofman A, Jonsson PV, Schmidt H, Lathrop M, Mosley TH, Au R, Psaty BM, Uitterlinden AG, Farrer LA, Lumley T, Ruiz A, Williams J, Amouyel P, Younkin SG, Wolf PA, Launer LJ, Lopez OL, Duijn CM, Breteler MM. Genome-wide analysis of genetic loci associated with Alzheimer disease. JAMA. 2010;303(18):1832–1840. doi: 10.1001/jama.2010.574. [PMC free article] [PubMed] [Cross Ref]
  • Sleegers K, Bettens K, Brouwers N, Engelborghs S, Miegroet H, Deyn PP, Broeckhoven C. Common variation in GRB-associated binding protein 2 (GAB2) and increased risk for Alzheimer dementia. Hum Mutat. 2009;30(2):E338–E344. doi: 10.1002/humu.20909. [PubMed] [Cross Ref]
  • Wigginton JE, Cutler DJ, Abecasis GR. A note on exact tests of Hardy–Weinberg equilibrium. Am J Hum Genet. 2005;76:887–893. doi: 10.1086/429864. [PubMed] [Cross Ref]
Articles from Springer Open Choice are provided here courtesy of
Springer